- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Idenix Pharmaceuticals Inc
Add to PortfolioIDIX:US
9.6800 USD 0.4000 3.97%As of 20:10:00 ET on 05/25/2012.
Snapshot for Idenix Pharmaceuticals Inc (IDIX)
| Open: | 10.2100 | Day's Range: | 9.5000 - 10.4000 | Volume: | 2,150,020 | Bid: | 9.6800 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 10.0800 | 52wk Range: | 4.0300 - 15.2500 | 1-Yr Rtn: | +108.62% | Ask: | 9.6900 |
Key Statistics for IDIX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.3500 |
| Est. EPS (USD) (12/2012) | -0.4940 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,048.64 |
| Shares Outstanding (M) | 108.33 |
| Enterprise Value (M USD) (ttm) | 943.38 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 14.7724 |
| Price/Sale (ttm) | 25.7450 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/08/2012 |
More IDIX Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for IDIX
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for IDIX
Idenix Pharmaceuticals Inc. is a biopharmaceutical company that discovers and develops drugs for the treatment of human viral and other infectious diseases. The Company is focusing on the treatment of infections caused by hepatitis B virus, hepatitis C virus, and human immunodeficiency virus (HIV).
| Ronald C Renaud Jr "Ron"President/CEO | David N StandringExec VP/Chief Scientific Ofcr |
| Douglas MayersExec VP/Chief Medical Officer | Daniella BeckmanSenior VP/CFO/Treasurer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page